|13th July 2020||Walter V Klemp||79,227||Exercise of derivative||$0.00|
|13th July 2020||Walter V Klemp||19,292||Payment by withholding||$0.86||$16,513.95|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms.